Pharma Reviews: Rs 150 per Covaxin dose to Centre not sustainable in long run: Bharat Biotech

In the absence of a dual pricing system, Indian vaccine and pharmaceutical companies risk being reduced to mere contract manufacturers with ...
Read more: Rs 150 per Covaxin dose to Centre not sustainable in long run: Bharat Biotech